June 15, 2021

Sen. Ron Johnson, R-Wis., sounded off Monday on “The Ingraham Angle” after Google-owned YouTube handed down a suspension of his account because he posted a video that contained information about Hydroxychloroquine, a relatively cheap prescription medication used to fight malaria and lupus.

Johnson said he was simply echoing statistics and information echoed by renowned New Jersey epidemiologist Dr. Stephen Smith about the potential that it would have worked well as an interim treatment for coronavirus infection while Americans were waiting for vaccines to be developed.

Host Laura Ingraham reported that YouTube will label any positive takes on the quinine medication “medical misinformation” – whether or not certified medical professionals like Smith were consulted.

Johnson said that early in the pandemic, the second “pillar” of pandemic response – early treatment – was ignored by the so-called experts.

“I’m not sure why, but the fact of the matter is because we didn’t have early treatment, I don’t know how many thousands of lives, tens of thousands of lives lost that didn’t need to be lost but it is a tragedy and blunder on the part of the health agencies,” he said.

Ingraham noted that the leader of one of those agencies, Dr. Anthony Fauci, was pushing remdesivir, an exponentially more expensive medication, to which Ingraham noted made for a much higher profit margin for Big Pharma – as she also noted the publicly-subsidized vaccine has been.

She asked Johnson whether such vested interests may have had an effect on the establishment’s early and continued condemnation of Hydroxychloroquine.

“There is a possibility. Hydroxychloroquine and Ivermectin treatments cost less than $50 per patient and Remdesivir costs $3,000,” he said, adding that he has heard reports of liver toxicity side effects from the latter.

Johnson added that if there were to have been an effective, easily-accessible early treatment, it greatly decreases the likelihood of emergency use authorizations for vaccines – which the current jabs are classified under while they await formal approval.

STORY